Cargando…
Evaluation of anaphylaxis risk by skin testing with coronavirus disease 2019 messenger RNA vaccines on patients with anaphylaxis
Autores principales: | Pienkowski, Marek M., Pienkowski, Stefan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482700/ https://www.ncbi.nlm.nih.gov/pubmed/34601091 http://dx.doi.org/10.1016/j.anai.2021.09.021 |
Ejemplares similares
-
Biphasic anaphylaxis after first dose of messenger RNA coronavirus disease 2019 vaccine with positive polysorbate 80 skin testing result
por: Pitlick, Mitchell M., et al.
Publicado: (2021) -
Immune parameters during anaphylaxis to messenger RNA coronavirus disease 2019 vaccines: Not the usual suspects?
por: de Chaisemartin, Luc, et al.
Publicado: (2022) -
Skin test after anaphylaxis to sugammadex
por: Hong, Sung Jin, et al.
Publicado: (2020) -
COVID‐19 vaccines and anaphylaxis—evaluation with skin prick testing, basophil activation test and Immunoglobulin E
por: Csuth, Àgnes, et al.
Publicado: (2022) -
Amikacin-triggered anaphylaxis: Should we go for skin test?
por: Samanta, Sukhen, et al.
Publicado: (2014)